Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to TDF/3TC/DTG versus maintaining NNRTI or boosted-PI regimens in virologically suppressed HIV infection in Thailand
TCTR20210409003Phase 3Recruiting
- Sponsor
- Atlanta Medicare
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir, tenofovir disoproxil fumarate, lamivudine in human immunodeficiency virus infection (HIV), sponsored by Atlanta Medicare. Started Dec 2020; status: recruiting.
02
Drugs
dolutegravirtenofovir disoproxil fumaratelamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20210409003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210409003.